HKC Corporation Draws Strong Media Attention at CES 2026

HKC Corporation Draws Strong Media Attention at CES 2026 GlobeNewswire January 09, 2026 LAS VEGAS, Jan. 09, 2026 (GLOBE NEWSWIRE) — HKC Corporation captured strong and sustained attention at the 2026 International Consumer Electronics Show (CES 2026), as its booth at the Las Vegas Convention Center quickly became one of the most active areas on […]

Radiant Ridge Energy Announces Strategic Partnership for 40MW Northern Alberta Natural Gas Power Development

Radiant Ridge Energy Announces Strategic Partnership for 40MW Northern Alberta Natural Gas Power Development GlobeNewswire January 09, 2026 Calgary, AB, Jan. 08, 2026 (GLOBE NEWSWIRE) — Radiant Ridge Energy Ltd., a leading provider of behind-the-meter natural gas power generation solutions, has entered into a Letter of Intent with an Alberta-based upstream producer to develop an

Post-Marathon Spending Surge in Sanya Signals the Rise of the “Racecation”

The Hainan (Sanya) Marathon, held over the last weekend of 2025, marked the inaugural Class A-certified event sanctioned by the China Athletics Association (CAA) since the commencement of operations in the Hainan Free Trade Port (Hainan FTP) under its independent customs and trade regulations. Hainan FTP’s advantages in easier visa access, air connectivity, duty-free trade,

Allegro to start production of osteoarthritis hydrogel as it prepares for clinical trials

Wallonia Minister of Economy and Employment Pierre-Yves Jeholet will perform opening ceremony on 9 January 2026 New cleanroom facility allows production of one million doses per year Ramping up for clinical development in osteoarthritis in 2026 Supports launch of Synoglide(TM) in veterinary markets worldwide Liege, Belgium – 9 January 2026 (08:30 CET) – Allegro NV,

Allegro to start production of osteoarthritis hydrogel as it prepares for clinical trials

Allegro to start production of osteoarthritis hydrogel as it prepares for clinical trials GlobeNewswire January 09, 2026 Wallonia Minister of Economy and Employment Pierre-Yves Jeholet will perform opening ceremony on 9 January 2026 New cleanroom facility allows production of one million doses per year Ramping up for clinical development in osteoarthritis in 2026 Supports launch

No serious adverse events to date in ongoing phase 1/2a clinical study of SYN321

Clinical study update Synartro is advancing the candidate drug SYN321, a novel intra-articular treatment for knee osteoarthritis, through a phase 1/2a clinical study focused on safety, tolerability, PK, and early efficacy signals. The study was initiated in August 2025 following approval from the Swedish Medical Products Agency (MPA) and the Swedish Ethical Review Authority. The

Invitation to media and analyst briefing for Ericsson Q4 2025 report

— Report to be released at approximately 7:00 AM CET on January 23, 2026 — One live video webcast for analysts, investors and journalists at 9:00 AM CET Ericsson's (NASDAQ: ERIC) financial report for the fourth quarter 2025 will be published at approximately 7:00 AM CET on January 23, 2026. The company will issue a

Pulsar Helium Reports Additional High-Pressure Gas Encounter at Jetstream #5 and Outlines Upcoming Testing Program

(TSX-V:PLSR),(OTC US:PSRHF),(Other OTC:PSRHF),(LSE – AIM:PLSR), THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR TO BE TRANSMITTED, DISTRIBUTED TO, OR SENT BY, ANY NATIONAL OR RESIDENT

Zealand Pharma enters agreement with DCAI to use Gefion AI supercomputer to accelerate drug discovery and support Metabolic Frontier 2030 strategy

(Copenhagen:ZEAL), Press release – No. 2 / 2026 Zealand Pharma enters agreement with DCAI to use Gefion AI supercomputer to accelerate drug discovery and support Metabolic Frontier 2030 strategy Access to Gefion, Denmark's flagship AI supercomputer, gives Zealand Pharma access to unprecedented computational power, enabling large-scale modeling, prediction, and optimization of drug candidates Agreement will

Scroll to Top